文献速递冠心病

PCI术后1年以上氯吡格雷与阿司匹林单药治疗比较

Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention.
PubMed 文献 · J Am Coll Cardiol · 2023-10-23

STOPDAPT-2试验5年随访结果显示,PCI术后1个月DAPT后氯吡格雷单药相比12个月DAPT后阿司匹林单药,主要终点(心血管结局或大出血)非劣效但未优效(11.75% vs 13.57%,HR 0.85,95%CI 0.70-1.05;非劣效P<0.001,优效P=0.13);心血管结局氯吡格雷优效(8.61% vs 11.05%,HR 0.77,95%CI 0.61-0.97,P=0.03),大出血无差异。

要点

  • PCI术后长期单药抗血小板,氯吡格雷主要终点非劣效于阿司匹林但未优效。
  • 氯吡格雷心血管结局优效(HR 0.77,95%CI 0.61-0.97),大出血无差异。
  • 1年 landmark 分析心血管事件氯吡格雷数值更低但未达统计学显著。

核心结论

  • PCI术后1年以上,氯吡格雷单药可能是阿司匹林的有吸引力的替代选择,具有边缘性缺血获益。

研究设计与样本

  • STOPDAPT-2为日本多中心、开放标签、裁决者盲法的随机临床试验。
  • 接受钴铬依维莫司洗脱支架PCI的患者按1:1随机分为氯吡格雷组(1个月DAPT后氯吡格雷单药)和阿司匹林组(12个月DAPT后阿司匹林单药),随访5年。
  • 共纳入3005例患者(年龄68.6±10.7岁;女性22.3%;急性冠脉综合征38.3%),2934例(97.6%)完成5年随访。

主要发现

  • 主要终点(心血管死亡、心肌梗死、卒中或明确支架血栓或TIMI大/小出血)氯吡格雷组11.75% vs 阿司匹林组13.57%(HR 0.85,95%CI 0.70-1.05;非劣效P<0.001;优效P=0.13)。
  • 心血管结局氯吡格雷组8.61% vs 阿司匹林组11.05%(HR 0.77,95%CI 0.61-0.97,P=0.03)。
  • 大出血氯吡格雷组4.44% vs 阿司匹林组4.92%(HR 0.89,95%CI 0.64-1.25,P=0.51)。
  • 1年 landmark分析:心血管事件氯吡格雷组6.79% vs 阿司匹林组8.68%(HR 0.77,95%CI 0.59-1.01,P=0.06);大出血3.99% vs 3.32%(HR 1.23,95%CI 0.84-1.81,P=0.31)。

临床怎么用

  • PCI术后需长期单药抗血小板时,氯吡格雷可作为阿司匹林的替代选择,尤其考虑缺血获益。
  • 选择时需综合评估缺血与出血风险,大出血风险两组无显著差异。

局限性

  • 开放标签设计,但裁决者盲法。
  • 研究在日本进行,结果外推需谨慎。
  • 1年 landmark分析中心血管事件差异未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It remains unclear whether clopidogrel is better suited than aspirin as the long-term antiplatelet monotherapy following dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). OBJECTIVES: This study compared clopidogrel monotherapy following 1 month of DAPT (clopidogrel group) with aspirin monotherapy following 12 months of DAPT (aspirin group) after PCI for 5 years. METHODS: STOPDAPT-2 (Short and Optimal Duration of Dual Antiplatelet Therapy 2) is a multicenter, open-label, adjudicator-blinded, randomized clinical trial conducted in Japan. Patients who underwent PCI with cobalt-chromium everolimus-eluting stents were randomized in a 1-to-1 fashion either to clopidogrel or aspirin groups. The primary endpoint was a composite of cardiovascular outcomes (cardiovascular death, myocardial infarction, stroke, or definite stent thrombosis) or major bleeding (TIMI major or minor bleeding). RESULTS: Among 3,005 study patients (age: 68.6 ± 10.7 years; women: 22.3%; acute coronary syndrome: 38.3%), 2,934 patients (97.6%) completed the 5-year follow-up (adherence to the study drugs at 395 days: 84.7% and 75.9%). The clopidogrel group compared with the aspirin group was noninferior but not superior for the primary endpoint (11.75% and 13.57%, respectively; HR: 0.85; 95% CI: 0.70-1.05; Pnoninferiority < 0.001; Psuperiority = 0.13), whereas it was superior for the cardiovascular outcomes (8.61% and 11.05%, respectively; HR: 0.77; 95% CI: 0.61-0.97; P = 0.03) and not superior for major bleeding (4.44% and 4.92%, respectively; HR: 0.89; 95% CI: 0.64-1.25; P = 0.51). By the 1-year landmark analysis, clopidogrel was numerically, but not significantly, superior to aspirin for cardiovascular events (6.79% and 8.68%, respectively; HR: 0.77; 95% CI: 0.59-1.01; P = 0.06) without difference in major bleeding (3.99% and 3.32%, respectively; HR: 1.23; 95% CI: 0.84-1.81; P = 0.31). CONCLUSIONS: Clopidogrel might be an attractive alternative to aspirin with a borderline ischemic benefit beyond 1 year after PCI.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Watanabe, Morimoto, Natsuaki, et al. Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2023. PMID: 37879491. doi:10.1016/j.jacc.2023.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。